Loading stock…

Dr. Sulaiman Al Habib Medical Services Group Company (4013) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Dr. Sulaiman Al Habib Medical Services Group Company

4013Market cap $21BPrice $60.8

Country🇸🇦Saudi Arabia

SectorHealthcare

IndustryHealthcare Services

Runs hospitals and clinics across Saudi Arabia, treating millions of patients yearly through its own facilities and insurance arm. It's one of the Gulf's largest private healthcare networks, riding Saudi Arabia's push to privatize medical care under Vision 2030.

In Bastion Portfolios?

52W Return-17%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+18%9

Revenue Forecast

Rev CAGR (1y)+13%7

Rev CAGR (3y)+11%7

Rev CAGR (5y)+14%9

Earnings Forecast

EPS Growth Y+1+10%7

EPS Growth Y+2+20%8

EPS Growth Y+3+15%7

Quality

Margins

EBIT Margin19%7

Net Income Margin17%7

Free Cash Flow Margin12%6

Debt

Net Debt/EBITDA2.14

Efficiency

ROE31%9

ROA11%9

Earnings Stability1010

GEAR+VERY STRONG94

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)282

P/E Ratio (Forward 3y)232

P/BV9.72

EV Multiples

EV/EBITDA Fwd232

EV/EBIT Fwd302

Yield

Free Cash Flow Yield2.1%4

Dividend Yield2.3%6

Momentum

Short term

1 month return-2%7

3 month return+6%8

YTD return-10%3

Mid term

Price vs 52wHigh83%6

1 year return-15%3

Long term

3 year return+3%3

5 year return+47%6

Risk Shield

Price Risk

Beta-0.010

Volatility21%9

Free Cash Flow

Free Cash Flow Margin12%6

Free Cash Flow Yield2.1%4

Quality

ROCE15%7

Earnings Stability1010

Net Debt/EBITDA2.14

02Growth

Is it actually growing, and how fast?

4013Dr. Sulaiman Al Habib Medical Services Group

Revenue FY25$3.0B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+14%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+10%7

EPS growth, FY27E+20%8

EPS growth, FY28E+15%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 14%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 15%/yr vs revenue 11%/yr).

WATCH

Revenue grew 18%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

4013Dr. Sulaiman Al Habib Medical Services Group

Total return Current123%

Price return Current109%

MOMENTUM RATING↗

AVERAGE51 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+6%8

YTD return-10%3

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return-15%3

3-year return+3%3

5-year return+47%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%) and over three months (+6%).

WATCH

Average long-term results. Multi-year returns are middling (+2.7% over three years and +47% over five), roughly average for the market.

It's down 15% over the past year, now 17% below its 52-week high. That is right in line with the market.

WEAKNESSES

The stock is underperforming so far this year (-10%).

BOTTOM LINE

Fresh Momentum

Short-term returns are strong but the long track record is thin. Momentum is building — confirmation from longer horizons would strengthen the case. The one thing to watch: the stock is underperforming so far this year.

04Value

Are you paying a fair price for it?

Stop guessing on Al Habib Medical. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

4013Dr. Sulaiman Al Habib Medical Services Group

Revenue FY25$3.0B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+18%9

Revenue, next 1Y+13%7

Revenue, next 3Y, CAGR+11%7

Revenue, next 5Y, CAGR+14%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+10%7

EPS growth, FY27E+20%8

EPS growth, FY28E+15%7

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 18%/yr over the last 3 years, ahead of 80% of companies worldwide.9/10

Revenue is set to grow 11%/yr over the next 3 years, ahead of most of the market.8/10

The runway holds up: revenue is set to grow 14%/yr over five years.9/10

Earnings are set to grow in step with sales (EPS about 15%/yr vs revenue 11%/yr).

WATCH

Revenue grew 18%/yr over the last 3 years; forecasts see it cooling to 11%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

4013Dr. Sulaiman Al Habib Medical Services Group

Total return Current123%

Price return Current109%

MOMENTUM RATING↗

AVERAGE51 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-2%7

3-month return+6%8

YTD return-10%3

MID & LONG-TERM▾SCORE

% of 52-week high83%6

1-year return-15%3

3-year return+3%3

5-year return+47%6

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (-2%) and over three months (+6%).

WATCH

Average long-term results. Multi-year returns are middling (+2.7% over three years and +47% over five), roughly average for the market.

It's down 15% over the past year, now 17% below its 52-week high. That is right in line with the market.

WEAKNESSES

The stock is underperforming so far this year (-10%).

BOTTOM LINE

Fresh Momentum

04Value

Are you paying a fair price for it?

Stop guessing on Al Habib Medical. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community